miR - 181b - 5p, downregulated in prostate cancer, directly targets the OSM 3’UTR, inhibits OSM mRNA and protein expression, decreases IL - 6 and AREG, and increases OPG, leading to the inhibition of bone metastatic activity in prostate cancer (51). Here, TNFRSF11B is linked to prostate carcinoma.